The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) consists of 5 research projects, 4 core resources, and the Career Development and Developmental Research Program. It draws on the complementary strengths of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center. Both centers have extensive experience in lymphoma research extending from basic investigation from basic investigation through translation to the clinic of a novel anti-HLA-DR monoclonal antibody and immunostimulatory CpG ODN. Mayo Clinic strengths include expertise with clinical trials including radiommunotherapy and correlative studies utilizing clinical lymphoma samples. The interaction of two comprehensive cancer centers on the UI/MC Lymphoma SPORE will allow for the performance of translational lymphoma research that would not be possible at each center alone. The overall theme of the SPORE is that Understanding the mechanisms responsible for the anti- tumor activity of anti-lymphoma monoclonal antibody therapy enhances our ability to treat lymphoma using a variety of modalities. The translational nature of the SPORE is highlighted by the inclusion of a clinical trial or population study at the onset in each research project. Specific projects are as follows: 1) Mechanism of action of anti-HLA-DR antibody therapy 2) Effector cells and anti-lymphoma antibody therapy 3) Clinical functional imaging and anti-lymphoma therapy 4) The impact of modifying antigen expression on the radioimmunotherapy of lymphoma 5) Prognostic implications of genotypic polymorphisms in lymphoma Core resources including Biostatistics, Biospecimens, Immunology, and Clinical Trials. All units within the SPORE will work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA097274-04S1
Application #
7114672
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ogunbiyi, Peter
Project Start
2002-09-11
Project End
2007-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
4
Fiscal Year
2005
Total Cost
$76,454
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598

Showing the most recent 10 out of 387 publications